🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,97 USD

Máx. histórico

89,55

118 días

Caída desde máximo

-22,98%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+1,25%

Cierre anterior

68,12

Rango de hoy

66,87 – 70,11

Volumen hoy

1.266.047

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,98%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 20 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
15/01/2020 50,21 52,02 49,55 51,50 +2,88% 4,92% 793.800
14/01/2020 48,23 50,29 47,83 50,06 +3,45% 5,10% 578.200
13/01/2020 50,48 50,48 47,90 48,39 -4,20% 5,11% 1.300.500
10/01/2020 51,75 52,35 50,24 50,51 -3,29% 4,07% 644.500
09/01/2020 51,54 53,29 51,38 52,23 +0,52% 3,71% 627.300
08/01/2020 51,56 52,64 51,22 51,96 +0,91% 2,75% 770.500
07/01/2020 49,29 52,11 49,10 51,49 +3,79% 6,11% 1.294.100
06/01/2020 47,73 49,69 47,55 49,61 +2,69% 4,48% 733.500
03/01/2020 47,42 48,84 47,37 48,31 -0,27% 3,10% 427.500
02/01/2020 48,36 48,49 47,50 48,44 +0,85% 2,05% 411.400
31/12/2019 47,41 48,24 47,23 48,03 +1,01% 2,13% 253.500
30/12/2019 48,90 49,04 47,13 47,55 -2,58% 3,92% 389.700
27/12/2019 48,96 49,07 48,34 48,81 -0,25% 1,50% 382.600
26/12/2019 49,49 49,63 48,87 48,93 -1,61% 1,54% 244.000
24/12/2019 49,55 49,77 49,02 49,73 +0,81% 1,51% 105.700
23/12/2019 48,80 49,68 47,75 49,33 +1,56% 3,95% 588.000
20/12/2019 48,48 48,75 47,82 48,57 +0,39% 1,92% 1.279.000
19/12/2019 48,27 48,75 47,67 48,38 +0,75% 2,25% 553.300
18/12/2019 49,03 49,27 47,75 48,02 -1,90% 3,10% 422.300
17/12/2019 47,99 49,09 47,94 48,95 +1,03% 2,40% 519.100
16/12/2019 48,78 49,12 48,03 48,45 +0,41% 2,23% 728.100
13/12/2019 47,39 48,75 47,20 48,25 +1,11% 3,27% 980.500
12/12/2019 48,03 48,86 47,28 47,72 -0,85% 3,29% 357.000
11/12/2019 48,88 49,47 47,92 48,13 -1,07% 3,18% 335.800
10/12/2019 48,00 49,20 47,96 48,65 +0,87% 2,58% 564.400
09/12/2019 49,32 49,75 48,14 48,23 -1,97% 3,26% 518.600
06/12/2019 49,70 50,17 48,84 49,20 -0,47% 2,68% 915.700
05/12/2019 50,79 50,96 49,11 49,43 -1,28% 3,64% 1.005.900
04/12/2019 50,12 50,22 48,98 50,07 +0,22% 2,47% 1.203.500
03/12/2019 48,01 50,32 48,01 49,96 +4,94% 4,81% 1.472.100